-
Mashup Score: 1Breyanzi Shows Durable Responses in R/R Marginal Zone Lymphoma - 13 day(s) ago
Breyanzi demonstrated a 95.5% response rate among patients with relapsed/refractory marginal zone lymphoma, as well as a durable safety.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet
-
Mashup Score: 3
Combining JNJ-1900 with Keytruda may improve distant control of lung cancer, explained by Dr. Jared Weiss.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet-
Improving Distant Control in Lung Cancer With JNJ-1900 and Keytruda @UNC_Lineberger #LungCancer https://t.co/FdPCInmkJO
-
-
Mashup Score: 4Cancer Recurrence, Getting Past the Anxiety - 14 day(s) ago
If there is ever an annual follow up CT scan that does not cause me significant anxiety, this year will be the one.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet-
If there is ever an annual follow up CT scan that does not cause me significant anxiety, this year will be the one. https://t.co/9uxChv2q0X
-
-
Mashup Score: 3
I became a colon cancer survivor after my 2020 diagnosis, and I share how my scars, mindset shifts and journaling helped me embrace this second chance.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet-
I became a colon cancer survivor after my 2020 diagnosis, and I share how my scars, mindset shifts and journaling helped me embrace this second chance. https://t.co/ZwmasZg08S https://t.co/QHP62eTKcx
-
-
Mashup Score: 5How Insurance Red Tape Threatens Timely Cancer Care - 15 day(s) ago
A study explores how prior authorization requirements; coverage stoppages and other red tape can generate barriers to life saving therapies in cancer care.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet-
❗A new @CancerCare study reveals how prior authorizations and coverage delays are harming patients with cancer — causing missed diagnoses, treatment interruptions, and overwhelming stress. #CancerSurvivor #MedEd 🔗 Read the full story and data here: https://t.co/3eIIMeTaLO https://t.co/gzY8KcYo09
-
-
Mashup Score: 4Explaining Brain Cancer and Metastases Updates for Patients - 15 day(s) ago
The 2025 ASCO Annual Meeting highlighted key advances in brain cancer and brain metastases for patients affected by the disease.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet-
The 2025 @ASCO Annual Meeting highlighted key advances in brain cancer and brain metastases for patients affected by the disease. @JSabari @Perlmutter_CC #ASCO25 #BrainCancer https://t.co/O7X0fWiQzx
-
-
Mashup Score: 6Can ctDNA Help Guide Surgical Decision Making in Breast Cancer - 15 day(s) ago
Dr. Rita Mukhtar and Dr. Joshua K. Sabari discuss the role of ctDNA to guide surgical decision-making after neoadjuvant chemo in breast cancer treatment.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet-
Can ctDNA Help Guide Surgical Decision Making in Breast Cancer @JSabari @Perlmutter_CC @UCLAHealth #BreastCancer https://t.co/lmfqItrlRR
-
-
Mashup Score: 2Personalized Therapy Helps Tailor Treatment for GIST - 15 day(s) ago
Dr. Breelyn Wilky explains that personalized treatments are helping improve outcomes for patients with gastrointestinal stromal tumors.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet-
Personalized Therapy Helps Tailor Treatment for GIST @breelynwilkyMD @CUCancerCenter #Oncolog #GIST https://t.co/GYISXrVCeL
-
-
Mashup Score: 2
Trials enrolling patients with relapsed leukemia, lymphoma and brain cancers, respectively, report early data showing safety/activity with novel therapies.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet-
🚨 New Clinical Trial Corner just dropped! We're spotlighting promising treatments in across #Leukemia, #Lymphoma & #BrainCancer this week. These early findings show safety, activity & hope for hard-to-treat diseases. 🔬 Read the full article: https://t.co/CSspPBlJGg
-
-
Mashup Score: 8Advancements Reshape Treatment for Non-Small Cell Lung Cancer - 15 day(s) ago
Dr. Prantesh Jain and Dr. Joshua Sabari delved into the numerous advances in NSCLC following 2025 ASCO, highlighting the RESILIENT-1 and NeoADAURA trials.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet-
Advancements Reshape Treatment for Non-Small Cell Lung Cancer @JSabari @Perlmutter_CC @jainprantesh @RoswellPark #LungCancer https://t.co/zqqtZutrZz
-
Breyanzi demonstrated a 95.5% response rate among patients with relapsed/refractory marginal zone #lymphoma, as well as a durable safety. @LiaPalomba @sloankettering @bmsnews https://t.co/7zdI1hlX9N